Why is "ALK positive lung cancer" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-04-03 08:22:09
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
This topic is not currently in the ranking.
Wikipedia Overview
ALK positive lung cancer is a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein, most frequently, the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to the anaplastic lymphoma kinase (ALK) gene. Less frequently, there will be novel translocation partners for the ALK gene, in place of EML4. This abnormal gene fusion leads to the production of a protein that appears, in many cases, to promote and maintain the malignant behavior of the cancer cells.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
From Diagnosis to Determination: Targeted Therapy for ALK-Positive Lung Cancer - Yale Medicine
-
Alecensa Improves 4-Year Survival in Early ALK-Positive Lung Cancer - Cure Today
-
ALK and Lung Cancer - American Lung Association
-
New Evidence Ties TP53 Alterations to Poorer Survival in ALK-Positive Lung Cancer - Physician's Weekly
-
Adjuvant Alectinib Impresses in Updated ALINA Results for ALK+ NSCLC - OncLive
-
Frontline Alecensa Extends Survival in Advanced ALK-Positive Lung Cancer - Cure Today
-
Pfizer QI Grants for ALK-Positive Lung Cancer (Spain) - fundsforNGOs
-
Genprex’s gene therapy shows promise for ALK-positive lung cancer - Investing.com
-
Advanced test predicts ALK inhibitor success in lung cancer - Drug Target Review
-
Lorbrena Effective as Initial Treatment of ALK-Positive NSCLC - National Cancer Institute (.gov)
-
Beyond Survival: The Psychosocial Toll of Living With ALK-Positive NSCLC - Physician's Weekly
-
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer - The New England Journal of Medicine
-
Alectinib approved in Scotland for ALK+ lung cancer post-surgery - ALK Positive Lung Cancer UK - Oncodaily
-
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer - Nature
-
“Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer - Cancer Health
-
FDA Approves Alectinib for ALK-Positive Lung Cancer - National Cancer Institute (.gov)
-
New Trials Advance Treatments for Lymphoma, Lung Cancer and Sarcomas - Cure Today
-
A retrospective study of postoperative targeted therapy in ALK-positive lung cancer - Nature
-
ALK-positive lung cancer: a moving target - Nature
-
ALK-Positive Lung Cancer in Focus - Cure Today
-
FDA Approves Alectinib For Initial Treatment of ALK-Positive Lung Cancer - National Cancer Institute (.gov)
-
Pfizer’s LORBRENA Wows in Long-Term ALK-Positive Lung Cancer Study - Inside Precision Medicine
-
Mechanisms of synergistic suppression of ALK-positive lung cancer cell growth by the combination of ALK and SHP2 inhibitors - Nature
-
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer - The New England Journal of Medicine
-
Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer - Nature
-
Lorlatinib in the second line and beyond for ALK positive lung cancer: real-world data from resource-constrained settings - Nature
-
Amanda Nerstad Shares Experience as Participant in ALK Vaccine Trial for Lung Cancer - Oncodaily
-
New collaborative effort aims to cure ALK-positive lung cancer - News-Medical
-
Pathological complete remission in ALK-positive lung cancer patient after multiple lines of conversion therapy - Frontiers
-
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer - The New England Journal of Medicine
-
Roche’s Alecensa receives NICE recommendation to treat ALK-positive lung cancer - PMLiVE
-
Lorlatinib produces ‘unprecedented’ disease progression delay in ALK -positive lung cancer - Healio
-
FDA approves Alecensa as leading-edge adjuvant therapy for ALK-positive lung cancer - Clinical Trials Arena
-
Lorbrena Yields “Unprecedented” Progression-Free Survival for ALK-Positive Lung Cancer - Cancer Health
-
Patient with Stage 4 ALK-Positive Lung Cancer Hasn’t Skipped a Beat, Thanks to Targeted Therapy - University of Rochester Medical Center
-
ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells - Nature
-
New First-Line Option for Advanced ALK-Positive Lung Cancer - medpagetoday.com
-
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer - The New England Journal of Medicine
-
Targeted Therapies Extend Overall Survival in Patients with Stage 4 ALK-Positive Lung Cancer - Cure Today
-
FDA Approves Lorbrena for ALK-Positive Lung Cancer - Cancer Health
-
Ceritinib Gets First-Line FDA Approval for ALK-Positive Lung Cancer - CancerNetwork
-
FDA Approves Lorbrena for Metastatic ALK-Positive Lung Cancer - Cancer Health
-
Health Watch: Targeting ALK Positive Lung Cancer - ABC30 Fresno
-
ALK Positive Summit Focuses on Community and Survivorship - University of Colorado Anschutz
-
In CROWN, Lorlatinib Shows Longest PFS in ALK-Positive Lung Cancer - medpagetoday.com
-
The ALK Life Study: Dr. Culver Shares Study Insights, Goals at WCLC 2024 - Docwire News
-
Roche Korea’s ALK-positive lung cancer drug gets expanded indication - koreabiomed.com
-
Nancee and Paul Pronsati help make Denver hub of research, treatment, and community for ALK-positive lung cancer - University of Colorado Anschutz
-
Up-front polytherapy for ALK-positive lung cancer - Nature
-
FDA Approves Brigatinib for Frontline ALK+ NSCLC - OncLive
-
Christian Rolfo, MD, PhD - Healio
-
J-ALEX: alectinib versus crizotinib in ALK -positive lung cancer - The Lancet
-
Pfizer’s Lorbrena extends life for patients with rare lung cancer - NBC News
-
Pfizer gets sales nod for ALK-positive lung cancer drug - koreabiomed.com
-
Successful application of lorlatinib in a 23-year-old patient with anaplastic lymphoma kinase ( ALK) -positive lung cancer and multiple brain metastases - Wiley Online Library
-
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer - The New England Journal of Medicine
-
ALK non-small cell lung cancer: Survival, symptoms, and more - Medical News Today
-
Redefining the Criteria for ALK Positive Lung Cancer | Newswise - Newswise
-
A mouse model for EML4-ALK -positive lung cancer - PNAS
-
Press Releases - News - Chinese University of Hong Kong. Faculty of Medicine
-
FDA approves new oral therapy to treat ALK-positive lung cancer - Medical Dialogues
-
CUHK-led Research Confirms Novel Targeted Therapy Twice as Effective as Current Standard Treatment for ALK-Positive Lung Cancer - The Chinese University of Hong Kong
-
Press Releases - News - Chinese University of Hong Kong. Faculty of Medicine
-
“Cancer Is Just One Part of Me”: Urvashi Prasad on Life With Stage 4 ALK-Positive Lung Cancer - Boldsky
-
Living with ALK-Positive Lung Cancer: Finding Hope Amidst The Battle With An Incurable Disease - Onlymyhealth
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.